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Most of our knowledge on the mechanisms of thyroid hormone (TH) dependent brain development is based on
clinical observations and animal studies of maternal/fetal hypothyroidism. THs play an essential role in brain
development and hormone deficiency during critical phases in fetal life may lead to severe and permanent brain
damage. Maternal hypothyroidism is considered the most common cause of fetal TH deficiency, but the problem
may also arise in the fetus. In the case of congenital hypothyroidism due to defects in fetal thyroid gland
development or hormone synthesis, clinical symptoms at birth are often mild as a result of compensatory maternal
TH supply. TH transporters (THTs) and deiodinases (Ds) are important regulators of intracellular triiodothyronine (T3)
availability and therefore contribute to the control of thyroid receptors (TRs)-dependent CNS development and
early embryonic life. Defects in fetal THTs or Ds may have more impact on fetal brain since they can result in
intracellular T3 deficiency despite sufficient maternal TH supply. One clear example is the recent discovery of
mutations in the TH transporter (monocarboxylate transporter 8; MCT8) that could be linked to a syndrome of
severe and non reversible psychomotor retardation. Even mild and transient changes in maternal TH levels can
directly affect and alter the gene expression profile, and thus disturb fetal brain development. Animal studies are
needed to increase our understanding of the exact role of THTs and Ds in prenatal brain development.
Keywords: Hypothyroidism, Brain development, Transporters, DeiodinasesThyroid hormone (TH) is essential for a number of
physiological processes and is particularly critical during
nervous system development [1-7]. In developing brain
THs stimulate and coordinate processes such as neuronal
proliferation, migration, growth of axons and dendrites,
synapse formation and myelination [4,7-22]. Disturbance
of these processes leads to abnormalities in the neuronal
network and may result in mental retardation and other
neurological defects, including impaired motor skills and
visual processing [23-27]. Hypothyroidism in adults has
been associated with mood symptoms and reduced quality
of life [16,28,29]. It is estimated that more than 12% of the
US population will develop a thyroid condition during
their lifetime, and an estimated 20 million Americans have
already some form of thyroid disease [30]. Besides, some
of the most prominent and common symptoms of thyroid
disease are those that result from the effects of TH on the
CNS [31].
THs act mainly by binding to nuclear TH receptors
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unless otherwise stated.directly controlling gene expression in neurons and glial
cells [11]. They exert their action mainly through binding
of 3,5,3′-triiodothyronine (T3) to nuclear receptors that
directly influence the expression of TH-regulated genes
[16]. Intracellular TH action is therefore dependent on
both the availability of T3 and its receptors [8,9,11,12].
TH uptake in cells is regulated by specific TH transporters
(THTs) and local activation and inactivation is regulated
by deiodinases (Ds) [32]. Generally, intracellular activation
or inactivation of L-thyroxine (T4) and T3 in turn is deter-
mined by three types of Ds, namely D1, D2, and D3
[24,33-35]. This local production and degradation of T3 is
extremely important because it allows regulating intracel-
lular T3 availability in developing brain regions/cell popu-
lations at least in part independently of the amount of T3
available in the rest of the body [32]. Before deiodination or
binding to TRs can occur, THs have to enter brain cells via
specific transmembrane THTs [36], including members of
the organic anion transporter family (OATP), L-type amino
acid transporters (LATs), Na+/Taurocholate cotransporting
polypeptide (NTCP), and monocarboxylate transporters
(MCTs) (Table 1) [37-39]. Particularly, monocarboxylate
transporter 8 (MCT8) has recently been identified as anis an Open Access article distributed under the terms of the Creative Commons
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Table 1 Types of thyroid hormones transporters and their
iodothyronine derivates [16]
Transportera Iodothyronine derivates Specificityb
MCT8 T3, T4, rT3, T2 +++
MCT10 T3, T4 ++
OATP1A1 T3, T4, rT3, T2, T4S, T3S, rT3S, T2S +




OATP1B1 T4, T3, T3S, T4S, rT3S
OATP1B2 T3, T4
OATP1B3 rT3, T4S, T3S, rT3S
OATP1C1 T4, rT3, T3, T4S ++
OATP2B1 T4 +
OATP3A1 (V1/V2) ++




LAT1 T3, T4, rT3, T2
LAT2
NTCP T4, T3, T4S, T3S ++
aThe human protein symbol is presented, if TH transport has been
demonstrated in different species including humans. bIf a transporter only
transports iodothyronine derivatives, specificity is high (+++). If fewer than five
other ligands are known, specificity is moderate (++). If more than five ligands
are known, the transporter is denoted as multispecific (+).
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also localized at the blood-cerebrospinal fluid barrier
(BCSFB) and the blood–brain barrier (BBB) and regulate
TH uptake from the general circulation at the level of the
choroid plexus and the capillaries throughout the brain
[40-43].
The importance of THTs for brain development was
clearly demonstrated when researchers were able to link
mutations in the human SLC16A2 gene coding for MCT8
to a previously described form of X-linked psychomotor re-
tardation, the Allan-Herndon-Dudley syndrome [44,45]. All
patients have a severe mental retardation, they cannot speak
and most of them are unable to sit upright, crawl, stand or
walk. Their thyroid phenotype is quite abnormal with a sub-
stantial decrease in plasma T4 and a more than twofold
increase in plasma T3 as well as an increase in thyroid-
stimulating hormone (TSH). Notably, preterm infants show
transient hypothyroxinemia without TSH elevation [46]. In
addition, the degree of neurodevelopmental delay in preterm
infants becomes severe according to the decreasing gesta-
tional age. Epidemiological and animal studies had shown
that maternal subclinical hypothyroidism had significant
negative impact on neurodevelopment [19,22,47]. To gainfurther insight in the pathogenic mechanisms underlying
these diseases, MCT8 knockout (KO) mice have been gen-
erated [42,48]. The serum TH parameters in MCT8 KO
mice are affected in the same way as in human patients but
surprisingly they seem to develop normally, without overt
neurological phenotype. Further analysis showed that the
entry of T4 into the brain was not disturbed while uptake of
T3 was diminished; suggesting that MCT8 is very important
for T3 transport across the BBB and/or BCSFB while the
passage of T4 is facilitated by other transporters [49]. The
overall T4 and T3 content of cerebrum and cerebellum were
decreased by more than 50%, but detailed morphological
studies as well as analysis of T3 target genes showed that
neuronal uptake of T3 was impaired in an area- or even
cell-specific manner. There were signs of a pronounced
hypothyroid status in the thyroid-releasing hormone (TRH)
producing neurons of the hypothalamic paraventricular nu-
cleus, a mild hypothyroid status in RC3 expressing neurons
of the striatum but an apparently normal thyroid status in
several cell types in the cerebellum [42]. It was concluded
that in mice, more than in humans, other THTs can com-
pensate for the lack of MCT8 in neurons, thereby protecting
the brain from severe neurological deficits. The critical re-
striction to T3 transport in the absence of MCT8 could be
located at the BBB rather than the plasma membrane of in-
dividual neurons [50]. This agrees with the hypothesis that
the high OATP1C1 expression in cerebral microvessels in
rodents, as opposed to the situation in humans, contributes
to the mild phenotype in MCT8 null mice [51]. Recently
also a combined MCT8- and D2-deficient mouse has been
described. Analysis of 34 target genes in the cerebral cortex
of single and double KO mice demonstrated that the expres-
sion of only 3 of them was affected by the elimination of
MCT8 alone while this number increased to 24 when both
MCT8 and D2 were absent, suggesting that D2 can partly
compensate for the decrease in TH uptake in MCT8 defi-
cient mice [52]. While several groups have studied the exact
localization of THTs at the level of the BCSFB in the chor-
oid plexus and at the level of the BBB in both macro- and
microvessels [51,53], only a few detailed reports are available
on their cell-specific distribution in other regions of the
brain. In situ hybridization (ISH) for MCT8 in murine brain
showed the highest signal in several layers of the cerebral
cortex and the hippocampus, in the amygdala, and many
basal ganglia. In the cerebellum, expression was predomin-
antly in the Purkinje cell layer. Using specific markers it
could be shown that MCT8 is predominantly expressed in
neurons, and to some extent in the tanycytes lining the third
ventricle [50,54,55]. Analysis of primary murine cell cultures
demonstrated high levels of MCT8 protein in neurons and
low levels in astrocytes and oligodendrocytes. Importantly,
MCT8 deficiency has important metabolic consequences in
the brain that could not be correlated with deficiency or ex-
cess of TH supply to the brain during adulthood [56]. Also,
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in tissue-specific TH transport and also contributes to the
generation of the unusual serum TH profile characteristic
for MCT8 deficiency. LAT1 showed the same expression
pattern as MCT8 [35]. MCT8 deficiency has important
metabolic consequences in the brain that could not be cor-
related with deficiency or excess of TH supply to the brain
during adulthood [56]. In human late fetal brain LAT2 was
found only in microglia while in perinatal mice it was also
widely expressed in neurons and astrocytes [35,55]. Informa-
tion on the ontogenetic changes in THT expression in
mammalian brain is quite scarce, especially for early devel-
opmental stages. In birds, THTs have been studied first in
quail in relation to their possible involvement in the regula-
tion of photoperiodicity at the level of the hypothalamus.
Four members of the OATP family were found in choroid
plexus: OATP1A1, OATP1B1, OATP1C1, and OATP3A2.
The ventro-lateral walls of the basal tuberal hypothalamus
showed strong expression of OATP1C1 and weak expres-
sion of OATP1B1 [58]. Analysis of chicken OATP1C1
substrate specificity in a cell culture system showed
that the protein is a highly specific transporter for T4
(Km 6.8 nM) [58]. While MCT8 mRNA levels in-
creased gradually between embryonic day (E) 4 and
E10, OATP1C1 expression showed a divergent pattern.
The overviews presented here are consistent with the
evolving view that the importance of THTs for proper
brain development [59].
On the other hand, deiodination is an important step
in the activation and inactivation of THs (Table 2)
[11,16]. D3 is essential for normal zebrafish embryonic
and early larval development [60]. D2 and D3 are the
main Ds expressed in brain and their distribution pat-
tern has been analyzed in a few vertebrate species. The
general picture appearing from studies in rodents is that
D2 is expressed primarily in glial cells while D3 is
expressed in neurons [24,61]. In rat forebrain D2 is
highly expressed in the external layers of the cerebral
cortex and in the hippocampus while in cerebellum the
signal is predominantly found in the granular layer. Co-
expression studies with Glial fibillary acidic protein
(GFAP) confirmed that in both brain regions D2 is
present in astrocytes and that it is also highly expressed
in ependymal tanycytes lining the third ventricle [61]. In
forebrain of the newborn rat D3 seems to be restricted
to a few specific regions such as the bed nucleus of the
stria terminalis and the amygdala but this expression is
no longer observed at postnatal day 10 [62]. In human
fetal cerebral cortex samples both D2 and D3 were de-
tected as early as 7–8 weeks of gestation [63]. Up to
20 weeks, D2 activity was rather high and comparable in
cerebral cortex and cerebellum. In contrast, D3 activity
was much higher in cerebellum than in cerebral cortex
and levels in cerebellum declined towards mid-gestation[64]. Expression of Ds has also been studied in avian
brain, mainly in chicken and quail [65]. A few research
groups investigated Ds expression in chicken brain dur-
ing embryonic development. Messenger RNA for all
three Ds is present in E4 brain [41] but for D1 this is
not accompanied by detectable activity throughout em-
bryonic development [66]. Both D2 mRNA and activity
increase gradually in all brain regions up to the day be-
fore hatching and then decrease again [41,66,67]. For D3
mRNA the pattern varies more between different brain
regions and activity levels do not always parallel expres-
sion data [41,66]. At the cellular level clear D2 protein
staining was detected in the ependymal cells of the chor-
oid plexus, the tanycytes of the third ventricle and the
Bergmann glial cells in cerebellum at E18 [68-70]. The
D3 protein was abundantly present in ependymal cells of
the choroid plexus in the days around hatching, and in
cerebellar Purkinje cells 1 day posthatch (C1), but not
yet at E18 where a weak signal was observed in the ex-
ternal granular layer [71]. Polymorphisms in D2 have
been associated with changes in circulating TH levels
[72] and with bipolar disorder [73]. No mutations in Ds
leading to an overt neurological phenotype, as for
MCT8, have been discovered so far. KO mice have been
generated for all three Ds, alone or in combination
[74-78]. In chicken, OATP1C1, MCT8 and D3 are
expressed in the choroid plexus and its precursors allow-
ing selective uptake of THs at the blood-cerebrospinal
fluid-barrier with subsequent inactivation of excess hor-
mone [79]. In contrast, the developing BBB does not ex-
press OATP1C1 or MCT8 but appears to be a site for
TH activation by D2. Expression of D3 in several sensory
brain centers may serve as protection against premature
TH action. Expression of D2 and MCT8 but not D3 in
the developing pituitary gland allows accumulation of
active THs even at early stages. MCT8 is widely
expressed in grey matter throughout the brain [79]. At
first sight, none of these mice presented a clear neuro-
logical phenotype and only the D3 KO mice showed
problems in reproduction and fetal survival. D1 KO and
D2 KO mice have normal circulating levels of T3 and no
compensatory changes were found in D2 or D3 activities
in the brain. Although the T3 content in brain of D2 KO
mice is substantially reduced, the expression of several
TH responsive genes is not or only mildly affected when
compared with hypothyroid mice [80]. D2 KO mice do,
however, show hearing loss and a retarded and abnormal
development of the cochlea [81]. The effects observed in
D2 KO mice were intensified following combined knock-
out of D1 and D2. More detailed analysis of their neuro-
logical functions showed no differences in reflexes but
some reduction in agility and possibly some problems
with vision [32]. While D3 KO mice have low circulating
levels of T4 and T3 during most of their life, perinatal
Table 2 General characteristics of the iodothyronine deiodinases [16]
Characteristic D1 D2 D3
Reaction kinetics Ping-pong Sequential Sequential
Reaction catalyzed
(Deiodination)
5 or 5' (ORD+IRD) 5' (ORD) 5 (IRD)
Main form T4-T3, rT3- T2 - T4- rT3, T3- T2 - T4- rT3- T2
Substrate preference 5: T4S>T3S>>T3, T4 T4>rT3 T3>T4
5': rT3, rT3S>T2S>>T4
Sulfation of substrates Stimulation Inhibition Inhibition
Substrate limiting KM 0.5 mM 1–2 nM 5–20 mM
In vitro cofactor limiting
KM
1–10 Mm DTT >10 mM DTT =70 mM DTT
Molecular mass (kDa) 29 30 32
Selenocysteine present present present
Homodimer Yes Yes Yes
Location - Liver, kidney, thyroid and pituitary. - Pituitary, brain, BAT, thyroida, hearta and skeletal musclea. - Brain, skin, uterus, placenta, fetus and in other
sites of the
maternal- fetal interface, such as the umbilical
arteries and veins.
Subcellular location - Liver: endoplasmic reticulum. - kidney: basolat-
eral plasma membrane
- Microsomal membranes - Microsomal membranes
Functions - Production serum T3 and the clearance of
serum rT3.
- Catalyzes the outer ring deiodination of T4 to T3 and is thus
important for the local production of T3.
- Catalyzes the inner ring deiodination of T4 to
rT3 and of T3 to 3,3'-T2.
Activity in
hypothyroidism
- Decrease in liver and kidney. - Increase in all tissues. - Decrease in brain.
- Increase in thyroid.
Low-T3 syndrome - Decrease - No change - No change
Active site residues - Selenocysteine histidine and phenylalanine. - (Seleno-)cysteine? - Selenocysteine
Human gene structure
and location
- 1p32-p33, 17.5 kb and 4 exons. - 14q24.3, 2 exons and 7.4-kb intron. - 14q32

















Table 2 General characteristics of the iodothyronine deiodinases [16] (Continued)
Iopanoic acid inhibitor +++ ++++ +++
Thiouracils ++++ -/+ -
Iodoacetate + ?
Flavonoids + +++ +++
aHumans only. T2 is diiodothyronine, T3 is triiodothyronine, rT3 is reverse triiodothyronine, T4 is thyroxine, T2S is diiodothyronine sulfate, T3S is triiodothyronine sulfate, T4S is thyroxine sulfate, rT3S is reverse











Table 3 General summary about the developmental thyroid hormone mechanisms (deiodinases, transporters, sulfotransferases and receptors) in human, rat
and chicken [16]
Human Rodent (rat) Chicken
Week post conception Day post conception Incubation day
1 W - D3 is detected in uterine wall. 1 GD D2 and D3 are observed in uterine wall. 5 h (blastula
stage)
- TRα mRNA is noticed and the levels markedly
increased during neurulation.
3 W - Thyroid gland begins. 7 -8.5 GD - Time of implantation process. 24 h - mRNA levels of D1, D2, and D3 are detected in
whole embryos.
- Very high D3 activity is detected in decidual
tissue.
4-6 W - TBG is observed in thyroid follicle cells at GD
29.
9 GD - Thyroid gland is first visible as an
endodermal thickening in the primitive
buccal cavity.
48 h - OATP1C1 expression appears.
- TRH is detected in fetal whole-brain at 4.5
weeks of gestation.
- TH is detected in rat embryotrophoblasts
- T4 is transferred via the placenta and has been
found in the gestational fluid sac from 4 to 6
W.
5-11 W - Maternal-embryo transfer of THs has been de-
tected in embryonic coelomic fluid and amni-
otic fluid.
- All the mRNAs encoding THTs are expressed in
placenta from 6 W and throughout pregnancy.
8 W - T4, T3 and rT3 are detected in coelomic/
amniotic fluids.
10 GD - T4, T3 and TRβ are detected in embryo/
trophoblast unit.
E2-E4 - T3, THTs, Ds and TRs are expressed in whole
embryos.
- TRs, D2 and D3 are noticed in fetal brain.
10 W - TSH is first detected in the fetal pituitary. E4 - OATP1C1 expression is more than 10-fold
higher in the telencephalon and diencephalon
compared to the mesencephalon and
rhombencephalon.
- D2 mRNA levels are highest in the
diencephalon.
8-10 W - The fetus is able to produce THs during this
period, but prior to that time, is totally
dependent on maternal THs.
E5 - TRα mRNA is widely distributed in fore-, mid-
and hind-brain.
11 W - TBG levels are detected in fetal serum and
increased through gestation.
E6 - T4 and T3 are detected in embryonic brain.
8-11 W - TRH is detected in fetal hypothalamus. E7 - D2 activity is observed in the brain before the












Table 3 General summary about the developmental thyroid hormone mechanisms (deiodinases, transporters, sulfotransferases and receptors) in human, rat
and chicken [16] (Continued)
12 W - T4 and T3 are observed in serum and brain. 13 GD - Placental circulation established. E8 - D2 mRNA is noticed in cell clusters throughout
the brain, particularly in rhombencephalon.
- Total serum T4 and T3 are low, free T4 is
relatively high.
- TRs and TH are observed in fetal brain. - OATP1C1 levels are declined substantially in all
brain regions.
- rT3 is noticed in serum relatively high. - D3 and D2 are detected in uterus and
placenta.
- TH synthesis begins in fetal thyroid.
- Decreased mRNA expression of OATP1A2 but
no change for OATP4A1 at 9–12 W compared
to term.
14 W - Expressions of mRNAs encoding MCT8, MCT10,
OATP1A2 and
14 GD - TRH mRNA is detected in neurons of the
fetal hypothalamus.
E4-E8 - D3 mRNA levels are markedly different in the
telencephalon and diencephalon but remain
stable, while the levels in mesencephalon and
rhombencephalon show a sharp decrease and
increase, respectively, during these days.
LAT1 are significantly lower prior to 14 W
compared to term
15 GD - Pituitary TSH mRNA expression begins. E9-10 - Several elements of the TH action cascade are
observed in the brain of embryos long before
their own thyroid gland starts hormone
secretion.
- TRH mRNA is detected in the developing
paraventricular nuclei of the hypothalamus.
16 W - D3 is observed in placenta and fetal epithelial
cells.
16-19.5 GD - TRs are observed in liver, heart and lung. E10 - The thyroid gland is fully functional.
- D3 and TRs are detected in fetal liver. - D1 and D2 are noticed in fetal tissues.
- D1 is noticed in heart and lung. - TRH is produced in low levels in
hypothalamus and increases approximately
threefold by GDI9.5.- Significant fetal TH secretion begins.
16-20 W - Duplication of TBG concentrations. 17 GD - TH synthesis begins in fetal thyroid E13 - Brain D2 is elevated at the peak of neuroblast
proliferation.
- TSH protein and Sulfotransferase are
observed.
18 -22 GD - The total T4 and T3 concentrations in
fetuses are increased dramatically because of
maturation of hormone synthesis of the fetal
thyroid gland.
E14 - The strong increase in intracellular T3 has been
observed.
- The coordination between THTs and Ds is
regulated both transplacental TH passage
from mother to fetus and the development
of the placenta itself through the progress
of gestation.
20 W - A steady increase in serum TH levels begins
and continues to term.
19 GD - Significant fetal TH secretion begins. E15 - Plasma T4 levels start rising markedly around
this day.
- Marked rise in serum TH but levels at birth











Table 3 General summary about the developmental thyroid hormone mechanisms (deiodinases, transporters, sulfotransferases and receptors) in human, rat
and chicken [16] (Continued)
22-32 W - Serum total and free T4 and T3 near and
below adult levels, respectively.
22 GD - Birth state. E16 - The decrease in DI activity in gonads is
combined with the relatively high D3 activity.
- Thyroid system is less developed.
- The HPT axis begins to mature during the
second half of gestation.
- As much as 17.5% of THs found in the
newborn are of maternal origin.
- A significant increase in T3 production and in
D2-activity and -mRNA expression are com-
bined with a decreased in D3 activity.
- LAT1 and OATP4A1 have been localized only
during the third trimester.




- Brain D2 activity is moderately elevated,
whereas D3 activity and mRNA expression are
highest between these days, followed by a
dramatic decrease thereafter.
- Complete maturation of thyroid system.
- MCT8 has been localized in the placenta in all
three trimesters of pregnancy.
- High concentrations of the different
iodothyronine sulfates, T4S, T3S, rT3S and T2S,
have been documented in human fetal and
neonatal plasma as well as in amniotic fluid
during the pregnancy.
10-20 PND - Serum TH levels continue to rise and are
higher than adult levels between these days.
E18 - D1 and D3 are expressed in the granule cells,
whereas D2 is found mostly in the molecular
layer and the Purkinje cells at that time.
14-50 PND - The levels of pituitary and serum TSH slowly
decrease from PND 14–16 until reaching
adult levels at PND 40.
E19 - The increase in brain T3 production correlates
with the appearance of TRβ expression in the
cerebellum, telencephalon and optic lobes.
- TRH levels increase to adult levels by PNDI7–
29, then decrease transiently between PND





- The brain is quite well developed at the time
of hatching.
- Adult TRH mRNA expression patterns are
observed at PND 22.
- The gradual increases in plasma T4 and
hepatic D1 are detected.
- D3 levels are decreased in spleen and
increased in skin and the lungs towards
hatching.
- T3 production seems to be elevated markedly
in liver.
- The rise of T4 is much more pronounced than
in plasma.
- Diminished T4 sulfation is detected.
30 PND Complete maturation of thyroid gland. E14-E19/20 - The T3 breakdown capacity by D3 is high in
liver but low in kidney.
E15/16-E20 - T4 levels in plasma increase gradually during
these days.
- In contrast to TRα expression which increases
gradually towards hatching, expression of TRβ
shows an abrupt elevation in late
development, especially in the cerebellum.
- The majority of tissues express D3 together











Table 3 General summary about the developmental thyroid hormone mechanisms (deiodinases, transporters, sulfotransferases and receptors) in human, rat
and chicken [16] (Continued)
E17-E20 - The levels of D3 activity noticed in liver are
rapidly drop by more than 90%.
- D1 levels in testis and ovary strongly decrease
around hatching.
E18–E20 - Brain D2 activity is moderately decreased,
whereas D3 activity is low.
E19-E20 - The low T3/T4 ratio is associated with high T3
breakdown in liver and with high T4
inactivation or T3 secretion in kidney.
E20-C0 - D1 activity gradually increases, reaching a
maximum around these period, and decreases
slowly to posthatch levels thereafter.
C1 (first day
posthatch)
- The expression of D1 is limited to the mature
granule cells and that of D3 to the Purkinje
cells exclusively, whereas D2 remains clearly
noticed in the molecular layer.
C2 - Highest D1-activities and -mRNA expressions
are detected in the liver, kidney, and intestine.
C1-C7 - The circulating T3/T4 ratio started to increase
gradually during the first week after hatching.
- Abbreviations: W is week, GD is gestation day, E is incubation day, PND is postnatal day, C is posthatch day, THs is thyroid hormones, TRH is thyroid releasing hormone, TSH is thyroid stimulating hormone, THTs is
thyroid hormone transporters, MCT is monocarboxylate transporter, OATP is organic anion transporter, Ds is deiodinases (D1, 2, 3), TRs is thyroid hormone receptors (TRα, β), T4 is Thyroxine, T3 is triiodothyronine, rT3 is












Ahmed Thyroid Research  (2015) 8:2 Page 10 of 12mice have markedly elevated serum T3 levels. Their
brain shows signs of thyrotoxicosis with high T3 levels
and increased expression of TH responsive genes in the
first days after birth. This changes to a hypothyroid status
by the time of weaning but in old D3 KO mice the brain
again turns to a thyrotoxic state despite reduced serum
TH levels. It has been shown that the transition from a
thyrotoxic to a hypothyroid status does not occur at the
same time in all brain regions [78,82]. D3 KO mice also
have impaired hearing, showing that both premature and
delayed cochlear maturation due to respectively T3 surplus
or deficiencies have permanent adverse impact on hearing
[83]. Further analysis of D3 KO mice also demonstrated
that D3 controls survival and maturation of cone photore-
ceptors and that D3 KO mice loose the majority of cones
in the developing retina through neonatal cell death [84].
TH signaling exerts regulatory roles in early Xenopus lae-
vis neurogenesis and second, that this period represents a
potential window for endocrine disruption [85]. In rodents
and humans, almost all T3 found in the fetal cerebral cor-
tex is generated through local deiodination of circulating
maternal T4 [64,86,87]. The fetal dependence on maternal
T4 is due (i) to the late development of the fetal thyroid
gland (in rodents thyroid function begins by E17–18 and
in humans by the 18–20 gestational week) and (ii) to the
increased activity of D2 and D3 in placenta and fetal tis-
sues [34,87-89]. As a consequence of the increased activity
of Ds in the fetus, serum T3 levels are maintained low and
the local generation of cerebral T3 from T4 is enhanced
[33,64,87]. To respond to this requirement, there is an
estrogen-dependent increase of maternal thyroid function
that transiently induces an increase of (i) circulating
thyroxine-binding globulin, affecting the T4 extra-thyroidal
pool, and of (ii) human chorionic gonadotropin, transiently
stimulating thyrocytes [90]. This increased maternal thyroid
function consequently needs increased iodine intake. In the
general population, even small variations in maternal thy-
roid function during pregnancy may affect the developing
head of the young child [21].
From the information above it is clear that THTs and
Ds are expressed in brain in a region- and cell specific
way (Table 3). It is also clear that deficiencies in THTs
or Ds can adversely affect neurodevelopment but the
neurological phenotypes are far from understood. The
defects are partly different from the ones observed due
to fetal hypothyroidism and the phenotype can also dif-
fer between humans and rodents. It seems therefore es-
sential to extend the research in two directions, towards
earlier developmental stages and towards other model
species. Additional research in different models using
conditional silencing will hopefully further improve our
understanding on how THTs, Ds and TRs cooperate
to regulate TR-mediated impact on vertebrate CNS
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